Home
About Us
>CEO Statement
>At a Glance
>Mission and Values
>Global Recognition
>History and Milestones
>Management Team
>Brochure
Therapeutic Focus
>Oncology
>Autoimmune Diseases
Products
>Pipeline Overview
>HMPL-004
>HMPL-011
>HMPL-012
>HMPL-013
>HMPL-813
Research & Development
>Drug Discovery Research
>Drug Development
>Facility and Capacity
Collaborations
>Overview
>Existing Partnerships
Media
>Key Facts
>Press Releases
>Featured Articles
Careers
Contacts
Press Releases
03/09/2010
HMPL-004 Ulcerative Colitis Abstract Selected for Distinguished Abstract Plenary Oral Presentation during Digestive Disease Week Conference
11/05/2009
Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved, Proceeding with Development and Partnership Plans
10/30/2009
Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Autoimmune Diseases
07/29/2009
Hutchison MediPharma Completes Patient Enrollment Ahead of Schedule for HMPL-004’s Global Phase IIb Trial for Ulcerative Colitis
07/28/2009
HMPL-012 (Sulfatinib) Receives Grant Support from Science and Technology Commission of Shanghai Municipality
07/13/2009
Hutchison MediPharma Announces Encouraging Results from Crohn's Disease Phase II Trial for HMPL-004
06/23/2009
Dr. Samantha Du Attends ChinaBio’s First Ever Partnering Forum as Keynote Panel Speaker
06/06/2009
Hutchison MediPharma Awarded “2009 China’s Most Innovative Enterprise”
05/19/2009
Dr. Samantha Du Invited as Panel Speaker in Super Session Hosted by Ernst & Young at 2009 BIO Conference”
04/30/2009
Hutchison MediPharma Welcomes Joining of a "Veteran"
First Prev
Next
Last
CountPage：1/4 RecordCount：40
Top
Back home
Print page
